Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Name

Click to order products descending

Display 15 Products per page

Tysabri
Read More
Tysabri is a humanized monoclonal antibody against the cellular adhesion molecule alpha-integrin.
July 31, 2018
Find out more
Tymlos transdermal patch
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH).
October 8, 2019
Find out more
Tymlos
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.
March 9, 2018
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
Tygacil
Read More
Tygacil (tigecycline; Pfizer) is the first of the glycylcycline class of antimicrobial agents. It targets and binds to the 30S subunit of the bacterial ribosomes.
June 19, 2015
Find out more
Tybost
Read More
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
December 11, 2015
Find out more
Tudorza Pressair
Read More
Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD)-associated bronchospasm, bronchitis, and emphysema.
July 31, 2018
Find out more
TS-1
Read More
TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.
December 11, 2017
Find out more
Truvada
Read More
Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs):
June 28, 2019
Find out more
Trumenba
Read More
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
September 3, 2019
Find out more
Trulicity
Read More
Trulicity (dulaglutide; Eli Lilly) is approved for the treatment of type 2 diabetes. It is a sustained-release formulation glucagon-like peptide-1 (GLP-1) agonist and therefore acts on the incretin system.
November 7, 2017
Find out more
Tropifexor
Read More
FXR is a nuclear receptor that regulates bile acid metabolism and signaling. Activation of the receptor inhibits bile acid synthesis from cholesterol via cytochrome P450 7A1 and increases bile acid conjugation, transport, and excretion. This protects the liver from the potentially harmful effects caused during bile acid accumulation. Tropifexor (Novartis/Pfizer) is a novel, highly potent, non-bile acid FXR agonist. It has demonstrated potent activity in rodent Parkinson’s disease models by measuring the induction of FXR target genes in tissues.
July 22, 2019
Find out more
Trogarzo
Read More
Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding one of the domains of the CD-4 protein, which inhibits a conformational change in CD-4 that is necessary to allow entry of HIV into T-cells.
July 28, 2019
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Trintellix
Read More
Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix.
March 29, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *